First Major Vitreous Removal Advancement in 40 Years to be
Available Through the New Stellaris Elite™ Vision
Enhancement System
LAVAL, Quebec, April 26, 2017 /CNW/ -- Valeant
Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX)
wholly owned subsidiary, Bausch + Lomb, today announced it has
received 510(k) clearance from the U.S. Food and Drug
Administration (FDA) for Vitesse™, the first and only hypersonic
device for vitreous removal, which uses a novel,
single-needle design and a continuously open-port system. This new
technology represents the first major vitreous removal innovation
in 40 years, and one that will be available exclusively on the
company's new Stellaris Elite™ Vision Enhancement
System.
"The successful clearance and upcoming launch of Vitesse is
another opportunity in our 2017 launch plan, which we believe will
provide truly innovative applications for retina surgeons and their
patients," said Joseph C. Papa, Chairman and CEO of Valeant.
"We look forward to bringing this next evolution, cutting-edge
technology to market on our new Stellaris Elite platform."
Earlier this month, Bausch + Lomb received 510(k) clearance from
the FDA for the Stellaris Elite Vision Enhancement System, the
company's next-generation surgical platform. The new machine
offers many new cutting-edge innovations, as well as the
opportunity to add upgrades and enhancements continuously, allowing
surgeons to customize their machines and expand their capabilities
more rapidly than ever before. Bausch + Lomb plans to launch
Stellaris Elite for retina applications this summer, which will
integrate both retina and cataract capabilities into a single
machine. It will offer additional functionality and a broad range
of accessories and probes, including Vitesse.
"I feel privileged to have been able to work with Bausch + Lomb
in the development of this new technology since its birth in the
lab in 2012. This is perhaps the first major technological change
in the way we remove the vitreous since the appearance of
guillotine vitrectors," said Paulo
Stanga, M.D., a professor of Ophthalmology and Retinal
Regeneration at the University of Manchester, and a vitreoretinal surgeon for
the Manchester Royal Eye Hospital based in Manchester, United Kingdom. "The new
hypersonic vitrector is a significant step forward as it has the
potential to lead to future advancements with various needle
configurations and gauge sizes."
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorders,
eye health, neurology and branded generics. More information about
Valeant can be found at www.valeant.com.
About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc.
company, is a leading global eye health organization that is solely
focused on protecting, enhancing and restoring people's eyesight.
Its core businesses include over-the-counter supplements, eye care
products, ophthalmic pharmaceuticals, contact lenses, lens care
products, ophthalmic surgical devices and instruments. Bausch +
Lomb develops, manufactures and markets one of the most
comprehensive product portfolios in our industry, which is
available in more than 100 countries.
Forward-looking Statements
This press release may contain forward-looking statements which
may generally be identified by the use of the words "anticipates,
"expects," "intends," "plans," "should," "could," "would," "may,"
"will," "believes," "estimates," "potential," "target," or
"continue" and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties discussed in the
Company's most recent annual or quarterly report and detailed from
time to time in Valeant's other filings with the Securities and
Exchange Commission and the Canadian Securities Administrators,
which factors are incorporated herein by reference. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements speak
only as of the date hereof. Valeant undertakes no obligation to
update any of these forward-looking statements to reflect events or
circumstances after the date of this press release or to reflect
actual outcomes, unless required by law.
Contact Information:
Elif McDonald
514-856-3855
877-281-6642 (toll
free)
elif.mcdonald@valeant.com
Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bausch--lomb-receives-510k-clearance-from-fda-for-vitesse-the-first-and-only-hypersonic-open-port-vitrectomy-system-300445840.html
SOURCE Valeant Pharmaceuticals International, Inc.